Cargando…

Sacubitril-Valsartan Increases Ultrafiltration in Patients Undergoing Peritoneal Dialysis: A Short-Term Retrospective Self-Controlled Study

AIM: There are few data about the effectiveness and safety of angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril-valsartan in end-stage renal disease (ESRD) patients undergoing peritoneal dialysis (PD). The present study was conducted to evaluate the association between sacubitril-valsartan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Fen, Zhang, Tingting, Yang, Sisi, Wang, Di, Zhuo, Qianqian, Qin, Xianhui, Gong, Nirong, Ai, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203730/ https://www.ncbi.nlm.nih.gov/pubmed/35721096 http://dx.doi.org/10.3389/fmed.2022.831541

Ejemplares similares

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
por: Ding, Ying, et al.
Publicado: (2023)

Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
por: Fu, Sha, et al.
Publicado: (2021)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

MMP‐7 affects peritoneal ultrafiltration associated with elevated aquaporin‐1 expression via MAPK/ERK pathway in peritoneal mesothelial cells
por: Yin, Yue, et al.
Publicado: (2021)

Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF
por: Guo, Yanhong, et al.
Publicado: (2022)

Current apparent treatment‐resistant hypertension in patients undergoing peritoneal dialysis: A multi‐center cross‐sectional study
por: Li, Dan, et al.
Publicado: (2022)

Effects of sacubitril‐valsartan in the treatment of chronic heart failure patients with end‐stage renal disease undergoing dialysis
por: Liu, Xiaoyan, et al.
Publicado: (2023)

A narrative review on sacubitril/valsartan and ventricular arrhythmias
por: Wei, Zhaoyang, et al.
Publicado: (2022)

High-Salt Diet Accelerated the Decline of Residual Renal Function in Patients With Peritoneal Dialysis
por: Gong, Nirong, et al.
Publicado: (2021)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Matrix Metalloproteinase-7 Associated with Congestive Heart Failure in Peritoneal Dialysis Patients: A Prospective Cohort Study
por: Xiao, Zhiwen, et al.
Publicado: (2023)

Hypokalemia Duration in the First Year Associated with Subsequent Peritoneal Dialysis-Associated Peritonitis: A Multicenter Retrospective Cohort Study
por: Huo, Zhihao, et al.
Publicado: (2022)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Data on effect of Sacubitril/valsartan on cardiac Remodelling in diabetic Cardiomyopathy rats
por: Ai, Jiao, et al.
Publicado: (2021)

Ultrafiltration Failure Is a Reflection of Peritoneal Alterations in Patients Treated With Peritoneal Dialysis
por: Krediet, Raymond T.
Publicado: (2018)

Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring
por: Böhm, Michael, et al.
Publicado: (2021)

Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension
por: Zhang, Yaling, et al.
Publicado: (2022)

Understand the difference between clinical measured ultrafiltrationand real ultrafiltration in peritoneal dialysis
por: Yu, Zanzhe, et al.
Publicado: (2021)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

Protective measures against ultrafiltration failure in peritoneal dialysis patients
por: Aguirre, Anna Rita, et al.
Publicado: (2011)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)

The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
por: Beck-da-Silva, Luís, et al.
Publicado: (2019)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
por: Xu, Yu, et al.
Publicado: (2023)

Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients
por: Yang, Liu, et al.
Publicado: (2022)

The history and mystery of sacubitril/valsartan: From clinical trial to the real world
por: Zhang, Mingsong, et al.
Publicado: (2023)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Valsartan/Sacubitril in heart failure and hypotension: how, when and why
por: Scardovi, Angela Beatrice, et al.
Publicado: (2019)

Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?
por: Bocchi, Edimar Alcides, et al.
Publicado: (2018)

A Rare Adverse Event of Rhabdomyolysis Caused by Sacubitril/Valsartan
por: Rawla, Prashanth, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3ac2hol2r3knfetnn8h0dd42b5